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Faisal Malik 2, John A. Lednicky 1 and Maureen T. Long 1
1Department of Comparative, Diagnostic, and Population Medicine, University of Florida, Gainesville, FL, United States,
2 Laboratory Medicine, Department of Pathology, Aga Khan University, Karachi, Pakistan
Several arboviruses are endemic to and co-circulate in Pakistan. In recent years,
Pakistan has observed a rise in arboviral infections. A cross-sectional study for arboviral
diseases, which included screening for Chikungunya virus (CHIKV), was initiated in
2015 to determine which pathogens were causing disease in patients presenting to
health care services. Exposure to CHIKV was verified via detection of viral nucleic
acids or virus-specific IgM with virus-specific neutralizing antibodies. Out of 997 enrolled
patients presenting with clinical features suggestive of arboviral disease, 102 patients
were positive for CHIKV IgM antibodies and 60 patients were positive for CHIKV
nucleic acids or neutralizing antibodies. The data presented here show that CHIKV has
been circulating in Pakistan since April of 2015. CHIKV infections were detected in
study subjects up to the conclusion of our enrollment period in July 2017. Syndromic
and clinical data show that arthralgia was associated with CHIKV as was rash, fever
greater than 38◦C, and lymphopenia. Neurological symptoms were reported in 49%
of CHIKV suspect patients and in 46.6% of confirmed infections. Acute disseminated
encephalomyelitis was diagnosed in 5% of confirmed infection and various manifestation
of encephalitis diagnosed in an additional 16.6% of patients with confirmed CHIKV
infections. CHIKV-exposed patients were just as likely to present with neurological
symptoms and encephalitis as patients with West Nile Virus infections but were 4.57
times more likely to have lymphopenia. This proportion of neurological symptoms may
be a complicating factor in countries where WNV and/or JEV co-circulate with CHIKV.
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INTRODUCTION
Chikungunya virus (CHIKV) is an enveloped, single-stranded, positive-sense RNA flavivirus
that is maintained in nature between humans and Aedes mosquitos. These vectors are found
throughout the world and are associated with a variety of viral outbreaks on all continents
except Antarctica. In recent years, Pakistan has experienced significantly increased burdens
of arboviral diseases including Dengue virus (DENV), West Nile virus (WNV), and Crimean
Congo Hemorrhagic Fever (CCHF) (1–4). Unfortunately, reporting and surveillance for these
diseases is limited due to the dissolution of the Pakistan Federal Ministry of Health in
2011.
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To assist in the development of arbovirus diagnostic
expertise, a Pakistan-US collaborative arbovirus surveillance
program was initiated in the Sindh region of Pakistan in
2015 with the aim to identify which arboviruses were causing
undifferentiated febrile illness in humans presenting to health
care services (5). This study made use of instruments and
procedures in accordance with CDC/WHO guidelines for
viral diagnosis which require isolation of virus and/or viral
nucleic acids or detection of virus specific IgM antibodies
with virus-specific neutralizing antibodies from patient serum
(6, 7). In addition, clinical and pathological data were
collected.
Here we report upon the active and persistent circulation of
CHIKV in humans in the southern region of Pakistan during
2015–2017. We also describe clinical and syndromic features of
CHIKV infections in the region. Analysis of patient data revealed
that neurological symptoms are present in a significant portion
of CHIKV exposed patients.
METHODS
Patient Enrollment and Case Definitions
Patients presenting with clinical symptoms indicative of arboviral
disease were enrolled under a cross-sectional, observational study
from April 2015 to July 2017 (5). This study aimed to identify
which arboviruses (DENV, WNV, Japanese Encephalitis virus
(JEV), and CHIKV) were the cause of acute undifferentiated
febrile illness in the Sindh region of Pakistan (5). Informed
consent and study procedures were reviewed and approved by the
Ethics Review Committee at Aga Khan University (#3183-PAT-
ERC-14) and the Institutional Review Board at the University of
Florida (#201500908). All enrolled subjects gave written consent
in accordance with the Declaration of Helsinki.
Patients presenting with syndromic findings of arboviral
disease were enrolled. Symptoms included: acute fever onset,
headache, myalgia, arthralgia, rash, or gastrointestinal symptoms
as stated in the CDC clinical description of arboviral illness (6).
Since neuroinvasive arboviruses are endemic to Pakistan, patients
presenting with symptoms indicative of neuroinvasive disease
were also enrolled. These patients required syndromic findings
of “acute onset of fever with headache, myalgia, stiff neck,
altered mental status, seizures, limb weakness, or cerebrospinal
fluid (CSF) pleocytosis” for enrollment (6). We also enrolled
patients presenting with acute disseminated myeloencephalitis
(ADEM), meningitis, encephalitis, acute flaccid paralysis,
cranial nerve palsies, focal neurological deficits, or
vertigo.
During December 2016 and January of 2017, we also
enrolled patients presenting with clinical syndromes reflecting
CDC/WHO case definitions for CHIKV which included “acute
onset of fever, polyarthralgia, headache, maculopapular rash,
myalgia, conjunctivitis, and nausea/vomiting (8, 9). This was
done in order to assist the physicians at our study sites with
the sudden influx of patients during a CHIKV outbreak. Patient
data was double-entered into a commercial spreadsheet program
(EXCEL, Microsoft, Redmond, WA).
Patients included males and females between 10 and 86 years
age meeting the enrollment criteria on the day of enrollment.
Patient samples were screened for malaria, influenza, CCHF,
typhoid, and sepsis. Patients positive for these conditions were
excluded from further testing or analysis. Patients were tested for
DENV NS1 antigen using a manufactured kit (Panbio Dengue
Early Rapid Test NS1 Antigen Capture Test, Alere, Waltham,
MA) following the manufacturer’s instructions. All NS1 negative
patients and patients presenting with neurological syndromes
that met the case criteria for neuroinvasive disease were evaluated
for exposure toWNV and JEV via IgM capture ELISA (West Nile
Detect, JE Detect Inbios, Seattle WA) and rt-PCR. Patients that
were negative for DENV NS1 antigen as well as WNV and JEV
IgM antibodies were then evaluated for CHIKV IgM antibodies
using a commercial IgM ELISA kit (CHIKjj Detect, Inbios, Seattle
WA).
RT-PCR
CHIKV IgM positive patients and few select patients with
severe polyarthralgia were screened for virus via rt-PCR. CHIKV
primers and probes were constructed based on the NS2A gene
(10). RNA was isolated from human serum samples using
a commercial RNA extraction kit (QIAamp Viral RNA kit,
QIAGEN, Valencia, CA) and reverse transcribed to cDNA using
a commercial cDNA kit (iScript cDNA Synthesis Kit, Bio-
Rad, Hercules, CA). PCR was performed using a commercial
reaction mix (iTaq Universal Probe Supermix,Bio-Rad), 500 nM
of forward and reverse primers and 175 nM of fluorogenic probe
labeled at the 5′ end with FAM reporter dye and the 3′ end
with a commercial quencher (BHQ-1, Biosearch Technologies,
Petaluma, CA) in a 20 µl total reaction volume. Cycling
conditions were as follows: 95◦C for 2min and 40 cycles of 95◦C
for 15 s and 60◦C for 1min.
Plaque Reduction Neutralization Test
(PRNT)
Patient samples that were negative for CHIKV via rt-PCR
were evaluated for CHIKV neutralizing antibodies via a plaque
reduction neutralization test (PRNT). The viral strain, CHIKV
181/25 (WRCEVA) was used for all testing. Dilutions of patient
serum (1:10 followed by 4-fold serial dilutions up to 1:160) were
mixed with an equal volume of MEM containing ∼50 plaque
forming units (PFU) of virus and incubated for 1 h at 37◦C. After
incubation, this mixture was inoculated onto confluent Vero cells
in 12-well plates, which were then incubated for an hour at 37◦C.
After incubation, the inoculum was removed and an overlay of
MEM with 0.5% methylcellulose, 2.5% FBS, non-essential amino
acids, penicillin, streptomycin, and amphotericin B was added to
the wells and the plates returned to the incubator until plaques
were visible. For counting, plaques were visualized by staining
with a fresh mixture of 50% methanol, 43% ethanol, 7% acetic
acid, and 0.1% wt/vol Coomassie blue. The antibody titer was
determined as the highest dilution that neutralized at least 50%
of the virus inoculum. A 50% reduction in plaques was set as the
cut-off for a positive test in order to detect low positive responses
in acute sera.
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Statistical Analysis
Statistical analyses were performed on clinical data using a
commercially available statistical software program (MedCalc
17.9.7). Logistic regression for dichotomous independent
variables was performed. Symptoms and clinical features listed
in CDC/WHO case definitions were set as the independent
variables (6). Odds ratios (OR) were calculated with 95%
confidence intervals. Ratios with a p-value < 0.05 were
considered significant. Pearson’s correlation coefficients and
associated p-values were calculated to identify potential
relationships between different variables in the data set. An
ANOVA with a Tukey-Kramer post-hoc test was performed on
non-dichotomous data. Chi-squared tests were used to verify
normal distribution of the population. A subset of 14 gender and
age matched patients enrolled in this study that were negative
for CHIKV via rt-PCR, IgM ELISA, and PRNT were included as
non-infected controls.
Diagnostic Criteria
Patients were confirmed positive for CHIKV exposure according
to CDC criteria which requires “isolation of viral nucleic acid OR
virus-specific IgM antibodies in serum with confirmatory virus-
specific neutralizing antibodies in the same or a later specimen
(6).” Thus, patients were classified as a CHIKV positive if they
were positive via rt-PCR or if they had IgM antibodies via ELISA
and a PRNT titer of at least 50% at any dilution. Patients that were
positive for CHIKV IgM antibodies but negative for CHIKV rt-
PCR and PRNT were classified as suspect since patient samples
may have been obtained during the brief period when only IgM
antibodies were present.
RESULTS
Epidemiology
Patient enrollment for the seroprevalence study began in April
of 2015. Over the course of 2 years, 997 patients with arboviral
disease symptoms were enrolled. Of these, 638 were evaluated
for CHIKV exposure via IgM ELISA. Of these 638 patients, 102
patients were IgM positive and from these, CHIVK was detected
in 29 patient serum samples via rt-PCR and an additional 29
patients possessed neutralizing antibodies for CHIKV.
Patients were confirmed positive for CHIKV exposure in all
five study sites starting in April 2015 to the end of enrollment
in July, 2017 with the majority of cases occurring prior to
the recognized outbreak of December 2016 (Figure 1). The
majority of cases were identified during the autumn and winter
months (Figure 1). In 2015, low level, year-round activity was
detected with peak activity occurring between late summer and
autumn with smaller increases in winter months. During 2015,
28 cases of CHIKV were detected with 82% occurring between
epidemiological week 32 and 45 (Figure 1). During 2016, 19
cases were detected during the same span of epidemiological
weeks, consistent with 2015, but a large increase in patients (n
= 24) testing IgM positive for CHIKV was detected beginning
in epidemiological week 50 and continuing through the next 21
weeks (Figure 1). Pearson correlation coefficients were calculated
to determine if there was any association between IgM ELISA
results with PRNT titers. There was a very weak association
between ELISA values and percent neutralization at the 1:10
serum dilution (r = 0.44). No other significant correlations
were found for clinical data, occurrence of symptoms,
and/or ORs.
FIGURE 1 | Incidence of CHIKV infections over a 27 month period. The number of IgM positive patients of CHIKV is plotted against epidemiological week.
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Patient Characteristics
Based on diagnostic testing, 107 patients were positive for
CHIKV via IgM, PRNT, and/or rt-PCR testing. Most of the
patients were from Karachi. Patients categorized as positive for
recent exposure included 54% that tested positive by IgM capture
ELISA, 52% of those were also positive for CHIKV nucleic
acids by rt-PCR, and 52% were positive by PRNT. Four patients
were positive for CHIKV via rt-PCR and PRNT (Table S1).
An additional five patients were negative for CHIKV IgM but
positive via rt-PCR.
The mean age of CHIKV suspect patients was 33.6 years
and the mean age of confirmed CHIKV patients was 37.6 years
(Table S1). Age was a significant predictor for exposure (p =
0.048) for confirmed cases however, significance was lost when
suspect cases were factored into the mean age (p = 0.977). Sixty-
four percent of patients with confirmed CHIKV infection were
males as were 57% of CHIKV suspect cases. Gender was not a
significant predictor of CHIKV exposure.
Clinical Manifestations of CHIKV Infection
Vital Signs
Temperature, heart rate, respiratory rate, and blood pressure
readings were recorded upon patient enrollment. The average
heart rate was 98 beats per minute (bpm) for CHIKV suspect
patients and 92 bpm for confirmed patients. A total of 35.3% of
suspect patients and 23.3% of confirmed patients had heart rates
greater than 100 bpm (Table 1). Average blood pressure readings
were within normal limits and not a significant predictor of
disease (Table 1). The average fever for CHIKV suspect patients
was 38.3◦C with an average duration of 5 days prior to hospital
admission. The average fever of CHIKV confirmed patients was
37.9◦C and a fever >38◦C was a significant factor for CHIKV
infection (p = 0.043). 64.7% of suspect patients and 38.3%
of confirmed patients presented with fevers greater than 38◦C
(Table 1). For both suspect and confirmed patients, respirations
were typically within normal limits and not associated with
exposure though 4% of suspect and 5% of confirmed patients had
respiratory rates greater than 25 breaths per minute (Table 1).
Clinocopathological Testing
Measurements for hepatic enzymes, lymphocytes, platelets,
and hemoglobin were recorded upon enrollment. In CHIKV
exposed patients, 83.3% suspect and 58.3% confirmed patients
tested for abnormally high levels of aspartate aminotransferase
(Table 2). 52.3% of suspect patients and 18.7% of confirmed
patients produced abnormal levels of alanine aminotransferase
(Table 2). Abnormal levels of alanine aminotransferase were
significantly less likely to occur for CHIKV confirmed patients
than CHIKV negative patients (Table 2). Platelet counts for both
suspect and confirmed CHIKV exposure patients were typically
normal with 34.3% of suspect and 9.8% of confirmed patients
exhibiting platelet counts indicative of either thrombocytopenia
or thrombocytosis (Table 2). Five of seven patients with
thrombocytosis also had neutrophil counts above normal (data
not shown). Both suspect and confirmed patients were far less
likely to exhibit thrombocytopenia thanCHIKVnegative patients
(Table 2). Over 40% of CHIKV suspect and confirmed patients
exhibited lymphopenia and CHIKV confirmed patients were 2.15
times more likely to have lymphopenia than CHIKV-negative
patients (Table 2). Hemoglobin levels were below normal for
42.5% of suspect and 40% of confirmed patients but were nomore
likely to occur than for CHIKV negative patients (Table 2).
Symptoms
Clinical findings at the time of presentation for both suspect and
confirmed CHIKV exposed patients included headache, fever,
rash, myalgia, arthralgia, eye pain, and gastrointestinal symptoms
(Table 3). Reporting of arthralgia occurred in 65% and 33.3% of
confirmed and suspect patients, respectively, and overall CHIKV
exposed patients were 3.06–12.67 times to exhibit joint pain
(Table 3). Myalgia occurred in 45% of confirmed patients and
53% of suspect patients (Table 3). Reporting of a petechial or
maculopapular rash occurred in 21.6% and 13.7% of confirmed
TABLE 1 | Vital statistics for CHIKV suspect and confirmed patients.
CHIKV suspect CHIKV confirmed
Mean (range) OR (95% CI) Mean (range) OR (95% CI)
N with abnormal values (%) N with abnormal values (%)
Heart Rate (bpm) 98 (42–155) 1.55 (0.42–5.69) 92 (12–127) 1.4 (0.37–5.3)
18 (35.3%) 14 (23.3%)
Systolic (mmHg) 118 (80–195)
176E+006
124 (81–230)
3 (8.3%) 5 (15%) 569E+006
Diastolic (mmHg) 69 (51–92) 71 (50–100)
2 (5.5%) 2 (6%)
Temperature (◦C) 38.3 (36.2–40) 2.93 (0.86–9.95) 37.8 (36–40.5) 1.4 (0.41–4.71)
33 (64.7%) 23 (38.3%)
Respiration (bpm) 20.25 (13–28) 0.16 (0.02–1.12) 20.89 (12–34) 0.21 (0.03–1.41)
2 (4%) 3 (5%)
Odds Ratios were calculated using a cohort of gender and age matched study patients that were negative for CHIKV.
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TABLE 2 | Clinical testing for CHIKV suspect and confirmed patients.
CHIKV suspect CHIKV confirmed
Mean (range) OR (95% CI) Mean (range) OR (95% CI)
N with abnormal values (%) N with abnormal values (%)
Aspartate aminotransferase (IU/L) 96.6 (16–172) 0.17 (0.02–1.23) 53.7 (16–103) 0.19 (0.03–1.43)
10 (83.3%) 7 (58.3%)
Alanine aminotransferase (IU/L) 59.9 (10–119) 0.20 (0.01–2.89) 40.5 (18–96) 0.13 (0.02–0.78)
11 (52.3%) 3 (18.7%)
Total Lymphocyte Count (109/L) 20.1 (4.3–40.4) 1.8 (0.52–6.20) 23.2 (2.7–58.5) 2.15 (0.64–7.21)
23 (43%) 32 (42%)
Platelet Count (109/L) 236 (20–957) 0.13 (0.03–0.56) 269 (19–629) 0.05(0.01–0.23)
15 (34.3%) 10 (9.8%)
Hemoglobin (g/dL) 12.2 (7.1–18.1) 1.8 (0.52–6.20) 12.4 (7.0–16.3) 0.97 (0.29–3.30)
23 (42.5%) 22 (40%)
Odds ratios were calculated using a cohort of gender and age matched study patients that were negative for CHIKV. Bold font indicates statistical significance.
TABLE 3 | Incidence of symptoms in patients with chikungunya infection for suspect and confirmed cases of exposure.
Status CHIKV confirmed (n) CHIKV IgM positive–(n) CHIKV confirmed OR (95% CI) CHIKV IgM positive OR (95% CI)
Eye pain 5.5% (8) 23.5% (12) 448E+006 514E+006
Hemorrhage 5% (3) 4% (2) 0.49 (0.04–5.81) 0.84 (0.08–8.71)
Rash 21.6% (13) 13.7% (7) 3.95 (0.47–32.97) 2.13 (0.24–18.83)
Gastrointestinal 53.3% (32) 39.2% (20) 1.31 (0.42–4.1) 0.75 (0.23–2.37)
Headache 45% (27) 51% (26) 0.96 (0.31–3.0) 1.04 (0.35–3.47)
Myalgia 45% (27) 53% (27) 0.56 (0.18–1.78) 0.69 (0.21–2.22)
Arthralgia 65% (39) 33.3% (17) 12.67 (2.6–61.74) 3.06 (0.62–15.15)
Altered mental status 16.6% (10) 6% (3) 0.82 (0.19–3.43) 0.24 (0.0.4–1.34)
Seizures 10% (6) 8% (4) 1.58 (0.18–14.27) 1.14 (0.12–11.06)
Weakness 6.6% (4) 8% (4) 153E+006 158E+006
Encephalitis 16.6% (10) 15.7% (8) 1.17 (0.22–6.08) 1.32 (0.25–6.94)
Respiratory 13.3% (8) 8% (4) 442E+006 162E+006
Urinary 6.6% (4) 11.8% (6) 1.03 (0.11–10.03) 1.79 (0.2–16.12)
ADEM 5% (3) 15.7% (8) 150E+006 468E+006
Vertigo 3.3% (2) 11.8% (6) 54.2E+006 449E+006
Any neurological symptoms present 46.6% (28) 49% (25) 5.48 (1.13–26.48) 6.25 (1.28–30.48)
Odds ratios were calculated using a cohort of gender and age matched study patients that were negative for CHIKV. Bold font indicates statistical significance.
and suspect patients, respectively, with these same patients
having ORs 3.95 and 2.13 for this clinical finding (Table 3).
Hemorrhage occurred in 5% and 4% of confirmed and suspect
patients, respectively (Table 3). Gastro-intestinal disturbances
occurred in 53.3% and 39.2% of CHIKV confirmed and suspect
patients, respectively (Table 3). Eye pain occurred in 13.3% and
23.5% of suspect and confirmed, respectively, while headache
occurred in 45% and 51% of patients in these classifications
(Table 3). Respiratory symptoms consisting mainly of shortness
of breath and/or difficulty breathing occurred in 13.3% and 8%
of confirmed and suspect patients, respectively (Table 3). Urinary
discomfort including burning micturition occurred in 6.6% and
11.8% of confirmed patients and suspect patients (Table 3). No
significant association of positive CHIKV status was detected
for headache, myalgia, eye pain, hemorrhage, gastrointestinal,
respiratory, or urinary symptoms (Table 3).
Symptoms of central nervous system (CNS) involvement
occurred in 49% of and 46.6% CHIKV suspect and confirmed
patients, respectively (Table 3). These symptoms included
vertigo, altered mental status, seizures, ADEM, and encephalitis.
Suspect patients were 6.25 times more likely to present with
neurological symptoms than the patients testing negative for
CHIKV (Table 3). Likewise, CHIKV confirmed individuals
were 5.48 times more likely to present with any of the
above neurological symptoms than negative patients (Table 3).
Altered mental status (i.e., confusion, disorientation, irritability,
drowsiness, and restlessness) was reported in 16.6% and 6% of
confirmed and suspect patients (Table 3). Seizures were reported
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FIGURE 2 | The incidence of CHIKV IgM+ patients and the reported incidence of arthralgia and neurological symptoms of a 27 month period.
in 10% and 8% of confirmed and suspect patients (Table 3)
Encephalitis, including meningoencephalitis and meningitis, was
reported in 16.6% and 15.7% confirmed and suspect patients
(Table 3). ADEM was reported for 5% of confirmed patients and
for 15.7% of suspect patients (Table 3). Vertigo was seen in 3.3%
and 11.8% of confirmed and suspect patients (Table 3).
No correlationwas detected between the presence of arthralgia
with neurological symptoms (r=−0.07629), or encephalitis (r=
−0.1344), or seizures (r = −0.1645). Of 93 IgM positive patients
(suspect and confirmed) presenting with CNS symptoms, 14 had
concomitant arthralgia. Four of 18 patients with encephalitis
had arthralgia. None of the patients with seizures had arthralgia.
August through November 2015 saw 15 of 23 patients with
neurological symptoms and 7 patients with arthralgia (Figure 2).
Neurological symptoms were reported in the majority CHIKV-
IgM+ patients prior to December 2016 whereas arthralgia was
reported in no more than half of the same patients (Figure 2).
Following the identification of CHIKV in December 2016,
arthralgia was reported for nearly all patients (p = 0.0082)
(Figure 2).
Syndrome Comparison
The CHIKV confirmed cohort was compared with a WNV
confirmed cohort to determine if any neurological symptoms
were more likely to be present for either virus (1). Symptoms of
TABLE 4 | Incidence of neurological symptoms in CHIKV and WNV confirmed
patients.
Symptom CHIKV (n) WNV (n) OR (95% CI)
Headache 45% (27) 42.3% (25) 1.00 (0.48–2.07)
Altered mental status 19.6% (10) 28.8% (17) 0.44 (0.17–1.10)
Seizures 10% (6) 15.2% (9) 0.51 (0.16–1.64)
Weakness 6.7% (4) 5% (3) 1.36 (0.29–6.35)
Encephalitis 19.6% (10) 13.5% (8) 1.3 (0.47–3.57)
ADEM 5% (3) 11.8% (7) 0.40 (0.1–1.62)
Vertigo 3.3% (2) 5% (3) 0.65 (0.11–4.07)
Amy neurological symptoms
present
46.6% (28) 49.1% (29) 0.87 (0.42–1.8)
Lymphopenia 53.3% (32) 20.3% (12) 4.57 (2.0–10.4)
Bold font indicates statistical significance.
CNS involvement included ADEM, encephalitis, vertigo, altered
mental status, seizures, and weakness. Odds ratios ranged from
0.40 to 1.36 for all symptoms indicating no significant association
for either virus for any symptom (Table 4). It was of interest to
note that patients with CHIKV infections were 4.57 times more
likely to present with lymphopenia than patients with WNV
infections (Table 4). While over half of CHIKV infected patients
exhibited abnormally low lymphocyte counts, only 20.3% of
WNV infected patients had low lymphocytes (Table 4).
Frontiers in Public Health | www.frontiersin.org 6 July 2018 | Volume 6 | Article 186
Barr et al. Neuroinvasive Chikungunya in Pakistan
DISCUSSION
This study demonstrates that CHIKV has been circulating in
Pakistan since 2015; at least 18 months prior to its recognized
emergence during the reported outbreak in December 2016
in Karachi, Pakistan. The data also show that neurological
symptoms are often present in CHIKV-infected patients
presenting with undifferentiated fever. This may be a
complicating factor in countries where other neuroinvasive
arboviruses co-circulate such as WNV and JEV. In areas were
viruses co-circulate, syndromic presentation can influence
diagnosis, clinical investigations, and patient care.
Based on their neurological symptoms, patients enrolled
prior to the 2016 CHIKV outbreak were routed for diagnostics
for WNV and JEV, which are known to cause neuroinvasive
disease and are endemic in the region. These patients were
ultimately negative for WNV and JEV IgM and rt-PCR and
were classified as “indeterminate exposure.” In light of the
2016 outbreak, these patients were retrospectively evaluated
for CHIKV exposure. The data show that, prior to the
2016 outbreak, 52% of CHIKV exposed persons exhibited
neurological symptoms and only 23% of patients reported
arthralgia. During and after the outbreak, 64% of patients
reported arthralgia and 40% reported neurological symptoms
however, few patients reported both symptoms. Whether this
was due to a function of CHIKV awareness or a different strain
of CHIKV is unknown. CHIKV was not suspected, especially
prior to the outbreak, due to the lack of arthralgia in most
patients. While neurological syndromes are not usually reported
for CHIKV outbreaks (11–13), encephalitis and other severe
neurological manifestations have been reported recently (14–
16).
The data presented here were not collected with the objective
of specifically identifying CHIKV. Most arboviruses of humans
have overlapping syndromes and these viruses often exhibit new
symptoms when emerging in new locales. Thus, any patient
meeting the case definition of arboviral disease was tested for
exposure to several arboviruses. As a result, the incidence of
clinical manifestation for the population presented here are
unique from what has been described elsewhere for this outbreak
(17–20). For instance, arthralgia is accepted as the defining
symptom of CHIKV infection and is often used as enrollment
criteria in most patient-based studies (21, 22). This is evident
in recent studies that report over 90% of patients exhibiting
arthralgia, both in Pakistan and the Western Hemisphere (17,
22, 23). Conversely, non-syndromic enrollment has reported
an incidence of the clinical manifestations of CHIKV that
reflect what is reported here (24). The data herein suggest
that neurological disease is a likely manifestation of CHIKV
infection as is the case for many other alphaviruses pathogenic
to humans.
Commercial IgM capture ELISA formats are the cornerstone
for detection of acute exposure to arboviruses. In areas where
closely related viruses co-circulate, cross-reactivity is a significant
problem and is the reason why the detection of virus specific
neutralizing antibodies or nucleic acid is required for a definitive
diagnosis (6, 7, 25, 26). In Pakistan, Sindbis virus (SINV) is
the only alphavirus known to circulate in the region which
could confound test results. While disease due to SINV has
not been reported in Pakistan, evidence of seropositive people
was reported in 1983 (27). Interestingly, both CHIKV and
SINV were detected with similar frequencies; around 1–1.5%
of 43 humans. While SINV has been detected in many
countries, actual human disease is limited and outbreaks are
often confined to the same locales, and almost exclusively in
northern Europe. The patients reported in this study were
defined by their clinical case criteria and CHIKV nucleic acids
were detected in many patients concurrent with patients with
antibody only evidence of CHIKV exposure. Notably, the rash
associated with SINV is pruritic and skin biopsies are often
positive for virus. Pruritic rash was not reported in any of our
patients.
For this study, a commercial IgM ELISA kit was used to
identify CHIKV suspect cases. While some diagnostics and data
sets are based on the presence of virus-specific neutralizing
antibodies, this may not correlate with acute exposure. A positive
PRNT with a negative IgM indicates historical exposure of at
least 4–6 months. Interpretation of PRNT testing alone must
rely on paired serum. Furthermore, neutralizing antibodies are
also highly cross-reactive with other closely related viruses
thus, neutralizing thresholds are not calculated below 50%
reduction of viral plaques (25, 26). Serum from 55 patients
with IgM antibodies to CHIKV were evaluated for the presence
of virus-specific neutralizing antibodies via PRNT. When the
neutralizing threshold for this data was set at 80% neutralization,
14 patients (25.4%) were interpreted as positive for CHIKV
exposure (Table S1). Since IgM positive patients would not
be expected to have a robust neutralizing response, a 50%
neutralization threshold was used which is consistent with WHO
diagnostic guidelines (7). Under these parameters, 29 (57.7%)
of patients were interpreted as positive for CHIKV exposure
(Table S1).
In conclusion, CHIKV has been circulating in Pakistan
since 2015 and our analysis indicates CNS symptomology
in over 40% of patients. This proportion of neurological
symptomsmay be resultant from the broader enrollment strategy
based on increased body temperature without respect to other
clinical abnormalities. CHIKV should be considered in patients
presenting with febrile disease irrespective of the presence of
acute arthritis. When multiple arboviruses co-circulate during
high seasonal activity, testing for multiple pathogens should
be performed to differentiate arbovirus etiological agents.
Accurate diagnosis of arboviral infections instructs the healthcare
industry of circulating viruses and can have a direct effect
on mosquito mitigation efforts since different vectors are
involved.
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